Durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA4) have been tested in phase 1b study and found to be safe with early evidence of clinical activity in relapsed NSCLC [65]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.